GlassScriptPhysician profile
Sahar Elsheikh
NPI 1518378850
$2,250.52
in general payments reported to CMS, 2019-2025
33 companies · $467 in 2025
The $467 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $287 · 2021: $145 · 2022: $369 · 2023: $389 · 2024: $421 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $347.27 | 2019-2025 | Mounjaro, Zepbound, Humulin |
| Novo Nordisk INC | $249.22 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $236.60 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $131.38 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $125.70 | 2019-2022 | |
| Inspire Medical Systems, INC. | $104.98 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $104.61 | 2022-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Medtronic, INC. | $96.51 | 2022-2024 | Minimed 780g |
| Dexcom, INC. | $88.75 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $76.50 | 2019-2021 | |
| Sanofi Pasteur INC. | $65.74 | 2022-2024 | |
| Averitas Pharma INC. | $65.35 | 2023-2024 | Qutenza |
| Xeris Pharmaceuticals, INC. | $65.21 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $55.11 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $49.58 | 2023-2024 | Bexsero, Shingrix, Arexvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.76 | 2022-2024 | Trulance, Xifaxan |
| Noven Therapeutics, LLC | $34.93 | 2023-2024 | Xelstrym |
| Mannkind Corporation | $30.84 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $28.53 | 2024 | Exparel, Iovera, Zilretta |
| Amryt Pharma Holdings LTD | $27.14 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $24.59 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $24.13 | 2024 | Spravato |
| Nevro Corp. | $22.19 | 2023 | Senza |
| Astellas Pharma US INC | $20.44 | 2025 | Veozah |
| Vivus LLC | $18.67 | 2024 | Qsymia |
| Shire North American Group INC | $17.50 | 2019 | |
| Antares Pharma, INC. | $15.56 | 2022 | |
| Amarin Pharma, INC. | $14.61 | 2022 | |
| Corium, LLC | $13.66 | 2024 | Azstarys |
| Gilead Sciences, INC. | $13.51 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.33 | 2023 | |
| Medtronic Minimed, INC. | $11.34 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahar Elsheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.